|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||4.76 - 5.05|
|52 Week Range||0.79 - 10.01|
|Beta (5Y Monthly)||-0.63|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here we take a look at the top ten best and worst performing biotech stocks this year Continue reading...
Update on COVID-19: CytoDyn is planning to lock and unblind the Phase 2 COVID-19 trial data later this week. Periodic safety review by Data Safety Monitoring Committee (DSMC).
2 CEOs see price change losses since their sales Continue reading...